Zobrazeno 1 - 10
of 66
pro vyhledávání: '"E. L. Michelson"'
Autor:
E. L. Michelson, Thomas W. Murphy, Christopher W. Stubbs, A. E. Orin, C. D. Hoyle, James Battat, H. E. Swanson, Eric Adelberger
Publikováno v:
International Journal of Modern Physics D. 16:2127-2135
APOLLO (the Apache Point Observatory Lunar Laser-ranging Operation) is a new effort in lunar laser ranging that uses the Apollo-landed retroreflector arrays to perform tests of gravitational physics. It achieved its first range return in October 2005
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b43f1d573ddc4b4c1d38cdf2ceab733
https://doi.org/10.1142/s0218271807011589
https://doi.org/10.1142/s0218271807011589
Autor:
E. L. Michelson, Thomas W. Murphy, A. E. Orin, C. D. Hoyle, Eric Adelberger, Christopher W. Stubbs, James Battat, H. E. Swanson
APOLLO (the Apache Point Observatory Lunar Laser-ranging Operation) is a new effort in lunar laser ranging that uses the Apollo-landed retroreflector arrays to perform tests of gravitational physics. It achieved its first range return in October 2005
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f9ed09fe046c2419078f35de1d585c4
https://doi.org/10.1142/9789814261210_0020
https://doi.org/10.1142/9789814261210_0020
Publikováno v:
American Journal of Physiology-Heart and Circulatory Physiology. 258:H1815-H1822
Adenosine exerts pronounced depressant effects on cardiac pacemakers. Previous studies in vitro have indicated that different pacemakers exhibit variable sensitivity to adenosine: ventricular greater than junctional greater than sinus node pacemakers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fecf7833a6414fb8ab4aeb669ecb5a60
https://doi.org/10.1152/ajpheart.1990.258.6.h1815
https://doi.org/10.1152/ajpheart.1990.258.6.h1815
Publikováno v:
Heart disease (Hagerstown, Md.). 2(6)
Tolerability is an important consideration in evaluating a new antihypertensive agent. This can be assessed informally by conventional patient interviews or more formally with the use of validated health-related quality of life (HRQL) measures assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6682d3c2ab0e8da6ad3d8d84b0293493
https://pubmed.ncbi.nlm.nih.gov/11728288
https://pubmed.ncbi.nlm.nih.gov/11728288
Autor:
A H, Gradman, A, Lewin, B T, Bowling, M, Tonkon, P C, Deedwania, A E, Kezer, J D, Hardison, D J, Cushing, E L, Michelson
Publikováno v:
Heart disease (Hagerstown, Md.). 1(2)
The antihypertensive efficacy and tolerability of the novel angiotensin-II (A-II) receptor blocker candesartan cilexetil and the prototype A-II receptor blocker, losartan, were compared in an 8-week, multicenter, double-blind, randomized, parallel-gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::758fd8708f0c4f0652dda6b10eabec58
https://pubmed.ncbi.nlm.nih.gov/11720604
https://pubmed.ncbi.nlm.nih.gov/11720604
Publikováno v:
American journal of hypertension. 14(6 Pt 1)
A large-scale, 8-week, open-label, clinical experience trial evaluated the efficacy of the angiotensin II receptor (AT1 subtype) blocker candesartan cilexetil (16 to 32 mg once daily) either alone or as add-on therapy in 6465 hypertensive patients. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8f3c9de1263cdbc5e460d3b6615b116f
https://pubmed.ncbi.nlm.nih.gov/11411737
https://pubmed.ncbi.nlm.nih.gov/11411737
Autor:
R A, Kloner, M, Weinberger, J L, Pool, S G, Chrysant, R, Prasad, S M, Harris, T M, Zyczynski, N K, Leidy, E L, Michelson
Publikováno v:
The American journal of cardiology. 87(6)
The comparative antihypertensive efficacy and tolerability of the angiotensin II receptor blocker candesartan cilexetil and the calcium channel blocker amlodipine were evaluated in an 8-week, multicenter, double-blind, randomized, parallel-group, for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d5e0598f301db71c9194ea929e27040b
https://pubmed.ncbi.nlm.nih.gov/11249891
https://pubmed.ncbi.nlm.nih.gov/11249891
Autor:
S, Oparil, J H, Levine, C A, Zuschke, A H, Gradman, E, Ripley, D W, Jones, J D, Hardison, D J, Cushing, R, Prasad, E L, Michelson
Publikováno v:
The American journal of cardiology. 84(3)
The efficacy, tolerability, and safety of the potent angiotensin II receptor blocker candesartan cilexetil were evaluated in 217 adult patients (68% men, 41% black) with severe systemic hypertension on background therapy with hydrochlorothiazide (HCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::39750fa7cc3ddf9aa826095a67ffb285
https://pubmed.ncbi.nlm.nih.gov/10496437
https://pubmed.ncbi.nlm.nih.gov/10496437
Autor:
C A, Zuschke, I, Keys, M A, Munger, A A, Carr, G N, Marinides, T L, Flanagan, D J, Cushing, J L, Hayes, E L, Michelson
Publikováno v:
Clinical therapeutics. 21(3)
This randomized, double-masked, placebo-controlled, forced-titration, parallel-arm study was designed to compare the blood pressure (BP)-lowering effect of candesartan cilexetil, a potent antagonist of the angiotensin II receptor subtype AT1, adminis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b0e11e828b19a6a6e8778aed4c1b3d22
https://pubmed.ncbi.nlm.nih.gov/10321416
https://pubmed.ncbi.nlm.nih.gov/10321416
Autor:
T P, Bell, V, DeQuattro, K C, Lasseter, D, Ruff, J D, Hardison, D, Cushing, A E, Kezer, E L, Michelson
Publikováno v:
The American journal of cardiology. 83(2)
The results of this randomized, double-blind, placebo-controlled, forced-dose titration study in a diverse population of hypertensive patients in the US indicate that candesartan cilexetil has clinically meaningful dose-related blood pressure-lowerin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ba3f4a7053313ea4bfeca622ba579508
https://pubmed.ncbi.nlm.nih.gov/10073836
https://pubmed.ncbi.nlm.nih.gov/10073836